18F-sodium Fluoride (NaF) PET to Replace Bone Scintigraphy: Safety and Efficacy Assessment
Infectious Disease | Bone Cancer | Articular Disease18F-sodium fluoride (18F-NaF) was already investigated numerous times in the last 40 years as a PET alternative to standard 99m-technetium-derived bone scintigraphy. However, lack of universal tracer availability and higher costs contributed to the failure of 18F-NaF to systematically supplant bone scintigraphy as a standard of care.
Recently, an isotope shortage crisis occurred and evidenced the need to have non-reactor-derived alternatives for many nuclear medicine procedures, including bone scintigraphy. Since 18F-NaF is cyclotron-produced, it could become a necessary alternative to bone scintigraphy in case of another worldwide isotope shortage.
The study aims to evaluate the safety profile of 18F-NaF injection. Moreover, a patient registry will be compiled in order to perform sub-studies on 18F-NaF diagnostic performance on diverse bone and articular diseases.
null
Conditions de participation
-
Sexe:
ALL -
Âges admissibles:
0 and up
Critères de participation
Inclusion Criteria:
* Patients for whom a 99mTc-biphosphonate bone scintigraphy is indicated;
* Pediatric patients for whom a 99mTc-biphosphonate bone scintigraphy is indicated for oncologic or infectious reasons
* Able to tolerate supine position
* Written consent
Exclusion Criteria:
* Healthy subjects
* Pregnancy
* Unable of maintaining supine position for more than 15 minutes
* Refusal to sign the consent form
* Known allergy or hypersensitivity to 18F-NaF or any of its constituants.
Lieu de l'étude
Université deSherbrooke
Université deSherbrookeSherbrooke, Quebec
Canada
Contactez l'équipe d'étude
CHUS
CHUSSherbrooke, Quebec
Canada
Contactez l'équipe d'étude
- Étude parrainée par
- Centre de recherche du Centre hospitalier universitaire de Sherbrooke
- Participants recherchés
- Plus d'informations
- ID de l'étude:
NCT04842071